Published in J Immunol on September 01, 2003
Gene Expression in MS Patients Before and During Treatment With Interferon-beta | NCT00202384
INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res (2008) 2.31
Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol (2004) 1.59
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One (2008) 1.43
Systems biology approaches for the study of multiple sclerosis. J Cell Mol Med (2008) 1.33
EDISA: extracting biclusters from multiple time-series of gene expression profiles. BMC Bioinformatics (2007) 1.31
Alignment and classification of time series gene expression in clinical studies. Bioinformatics (2008) 1.22
Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. Expert Rev Clin Immunol (2014) 0.94
Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks. J Neurol (2008) 0.88
Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients. Pharmacogenomics (2009) 0.87
Differential and trajectory methods for time course gene expression data. Bioinformatics (2005) 0.84
Wigwams: identifying gene modules co-regulated across multiple biological conditions. Bioinformatics (2013) 0.83
Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta. Ann N Y Acad Sci (2009) 0.82
Gene expression studies in multiple sclerosis. Curr Genomics (2007) 0.81
Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J Neurol (2007) 0.80
Endogenous and recombinant type I interferons and disease activity in multiple sclerosis. PLoS One (2012) 0.79
Neutralizing antibodies against interferon-Beta. Ther Adv Neurol Disord (2008) 0.78
Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ. PLoS One (2017) 0.75
MultiFacTV: module detection from higher-order time series biological data. BMC Genomics (2013) 0.75
Can blood gene expression predict which patients with multiple sclerosis will respond to interferon? PLoS Med (2005) 0.75
Effect of relapses on development of residual deficit in multiple sclerosis. Neurology (2003) 2.60
Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med (2006) 2.50
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry (2013) 1.69
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2010) 1.59
Information-theoretic metrics for visualizing gene-environment interactions. Am J Hum Genet (2007) 1.47
Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. J Neuroimmunol (2012) 1.46
Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.44
Semantic integration to identify overlapping functional modules in protein interaction networks. BMC Bioinformatics (2007) 1.43
Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci (2007) 1.39
BioStar models of clinical and genomic data for biomedical data warehouse design. Int J Bioinform Res Appl (2005) 1.28
Risk of bone loss in men with multiple sclerosis. Mult Scler (2004) 1.27
A novel functional module detection algorithm for protein-protein interaction networks. Algorithms Mol Biol (2006) 1.25
AMBIENCE: a novel approach and efficient algorithm for identifying informative genetic and environmental associations with complex phenotypes. Genetics (2008) 1.24
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol (2006) 1.23
Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation (2011) 1.11
VizStruct: exploratory visualization for gene expression profiling. Bioinformatics (2004) 1.06
Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids (2005) 1.04
Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal Chem (2010) 1.01
An information theoretic approach for analyzing temporal patterns of gene expression. Bioinformatics (2003) 1.00
Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol (2007) 0.98
Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol (2009) 0.97
Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci (2003) 0.96
Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. Expert Rev Neurother (2011) 0.96
Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet (2007) 0.93
Information-theoretic gene-gene and gene-environment interaction analysis of quantitative traits. BMC Genomics (2009) 0.93
Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. PLoS One (2013) 0.92
Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. J Neurol Sci (2011) 0.92
Comparison of information-theoretic to statistical methods for gene-gene interactions in the presence of genetic heterogeneity. BMC Genomics (2010) 0.92
The interaction index, a novel information-theoretic metric for prioritizing interacting genetic variations and environmental factors. Eur J Hum Genet (2009) 0.92
Information-theoretic identification of predictive SNPs and supervised visualization of genome-wide association studies. Nucleic Acids Res (2006) 0.90
Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol (2009) 0.89
Assessment of Markov-dependent stochastic models for drug administration compliance. Clin Pharmacokinet (2003) 0.89
A probabilistic framework to predict protein function from interaction data integrated with semantic knowledge. BMC Bioinformatics (2008) 0.88
A classroom-administered simulation of a television campaign on adolescent smoking: testing an activation model of information exposure. J Health Commun (2007) 0.88
Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol (2008) 0.87
Risk factors for chronic cerebrospinal venous insufficiency (CCSVI) in a large cohort of volunteers. PLoS One (2011) 0.87
Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J Neuroimmunol (2006) 0.87
SPLINDID: a semi-parametric, model-based method for obtaining transcription rates and gene regulation parameters from genomic and proteomic expression profiles. Bioinformatics (2005) 0.85
Boron-based inhibitors of acyl protein thioesterases 1 and 2. Chembiochem (2012) 0.84
VizStruct for visualization of genome-wide SNP analyses. Bioinformatics (2006) 0.84
Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Mult Scler (2006) 0.84
Patterns of dietary and herbal supplement use by multiple sclerosis patients. J Neurol (2011) 0.84
Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther (2008) 0.83
MHC-dependent desensitization of intrinsic anti-self reactivity. Cancer Immunol Immunother (2008) 0.83
Comparison of the immunomodulatory effects of the plant sterol beta-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. Int Immunopharmacol (2008) 0.83
Arterial, venous and other vascular risk factors in multiple sclerosis. Neurol Res (2012) 0.83
Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. Mult Scler (2003) 0.83
Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients. PLoS One (2011) 0.83
Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. BMC Neurol (2012) 0.83
Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients. J Neuroimmunol (2006) 0.83
Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol (2007) 0.82
MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J Neurol (2009) 0.82
Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. J Neuroimmunol (2013) 0.82
Multiple sclerosis pathology in the normal and abnormal appearing white matter of the corpus callosum by diffusion tensor imaging. Mult Scler (2004) 0.82
CASCADE: a novel quasi all paths-based network analysis algorithm for clustering biological interactions. BMC Bioinformatics (2008) 0.81
MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. BMC Neurol (2014) 0.80
ESPD: a pattern detection model underlying gene expression profiles. Bioinformatics (2004) 0.80
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer (2014) 0.80
A two-stage search strategy for detecting multiple loci associated with rheumatoid arthritis. BMC Proc (2009) 0.80
Vitamin D and multiple sclerosis. Neurologist (2012) 0.80
Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS. Nat Rev Neurol (2012) 0.80
Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. J Neurol (2012) 0.80
Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain neurovasculature. J Neuroinflammation (2013) 0.80
Analysis of pharmacokinetics, pharmacodynamics, and pharmacogenomics data sets using VizStruct, a novel multidimensional visualization technique. Pharm Res (2004) 0.79
Interferon inhibitory activity in patients with multiple sclerosis. Arch Neurol (2006) 0.79
A hybrid Markov chain-von Mises density model for the drug-dosing interval and drug holiday distributions. AAPS J (2015) 0.78
Commentary: stochastic phenomena in pharmacokinetic, pharmacodynamic and pharmacogenomic models. AAPS J (2005) 0.78
Phytosterols ameliorate clinical manifestations and inflammation in experimental autoimmune encephalomyelitis. Inflamm Res (2010) 0.78
Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions. CNS Drugs (2014) 0.78
Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. Pathophysiology (2010) 0.78
Vitamin D and multiple sclerosis: can vitamin D prevent disease progression? Expert Rev Neurother (2011) 0.78
An information theory analysis of gene-environmental interactions in count/rate data. Hum Hered (2012) 0.78